Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond



Rating:

Share or cite this content

Citations should be made in the following way:
S. Schneider (Zürich, Switzerland), L. Mayer (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), C. Berlier (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), L. Tan (Zürich, Switzerland), K. Bloch (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland). Effects of a daytrip to high altitude (2500m) in pulmonary hypertension.. 3605

Member's Comments

No comment yet.

Related content which might interest you: Metabolic effects of hypoxia and sleep at high altitude (5050 m) Source: Annual Congress 2010 - Lung disease and mountain sickness: the importance of ventilatory control Year: 2010 Estimation of effects of intermittent exposure to the altitude of 3200m on hypoxic pulmonary vasoreactivity Source: Eur Respir J 2004; 24: Suppl. 48, 110s Year: 2004 Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial Source: ERJ Open Res, 7 (4) 00314-2021; 10.1183/23120541.00314-2021 Year: 2021 Increased body weight and reduced vital capacity correlate with augmentation of pulmonary hypertension during intermittent hypoxia at an altitude of 3800 m according to five years‘ follow up Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Effect of dexamethasone prophylaxis on sleep and breathing disturbances in high altitude pulmonary edema (HAPE) susceptible subjects after rapid ascent to 4559m Source: Annual Congress 2010 - Lung disease and mountain sickness: the importance of ventilatory control Year: 2010 Higher pulmonary artery pressure in children than in adults upon fast ascent to high altitude Source: Eur Respir J 2008; 32: 664-669 Year: 2008 Effects of intermittent exposure to high altitude (HA) on pulmonary haemodynamics: a prospective study Source: Eur Respir J 2003; 22: Suppl. 45, 268s Year: 2003 Blood eosinophil levels and exacerbations in a cohort of biomass and tobacco-related COPD patients at high altitude (2600 m) Source: Virtual Congress 2020 – Health effects of inhaled nicotine devices: from smoking to vaping and heated tobacco Year: 2020 Effects of phosphodiesterase type 5 inhibitor on pulmonary hemodynamics in the patients with high altitude pulmonary hypertension (results of 12 week randomized, blind, placebo-controlled study) Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 High-altitude disease Source: Respipedia Article Year: 2017 State of β-adrenoreceptors in pulmonary hypertension due to COPD at high altitude Source: Eur Respir J 2002; 20: Suppl. 38, 99s Year: 2002 Pulmonary hypertension due to COPD at high altitude Source: Eur Respir J 2002; 20: Suppl. 38, 99s Year: 2002 Pulmonary hemodynamics in highlanders with high altitude pulmonary hypertension in 1 year after finishing of sildenafil treatment Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Profile of high altitude pulmonary edema(HAPO) among young healthy reinductees. Source: International Congress 2018 – Occupational and environmental lung diseases: inhaled air quality and health effects Year: 2018 Effect of altitude on ventilatory pattern in élite climbers during the acclimatization at 5200m Source: Eur Respir J 2005; 26: Suppl. 49, 349s Year: 2005 Cerebral oxygen availability limits exercise performance of lowlanders with chronic obstructive pulmonary disease (COPD) travelling to 2590m Source: International Congress 2015 – Unravelling the mechanisms of symptoms and exercise limitationas in disease Year: 2015 Travel to high altitude with pre-existing lung disease Source: Eur Respir J 2007; 29: 770-792 Year: 2007 Sildenafil increases exercise capacity by alleviation of hypoxic pulmonary hypertension at low altitude and at Mount Everest base camp Source: Eur Respir J 2004; 24: Suppl. 48, 108s Year: 2004 Endothelin and high altitude pulmonary hypertension Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Patients walking more than 450 m in 6 minutes at diagnosis of pulmonary arterial hypertension: baseline characteristics and prognostic factors Source: Annual Congress 2009 - Pulmonary circulation Year: 2009